Literature DB >> 22544696

Vitamin D in chronic kidney disease.

Yahn-Yir Chau1, Juhi Kumar.   

Abstract

Vitamin D deficiency is widespread in both the pediatric and adult chronic kidney disease (CKD) population. CKD is characterized by dysregulation of vitamin D and mineral metabolism. Secondary hyperparathyroidism and its management puts patients with CKD at increased cardiovascular risk. Emergence of experimental and some clinical data suggesting beneficial effects of vitamin D on proteinuria, blood pressure, inflammation and cardiovascular outcomes has pushed it to the center stage of CKD research. Pediatric data on vitamin D dysregulation and its consequences are still in its infancy. Ongoing prospective studies such as Chronic Kidney disease in Children (CKiD) and the Cardiovascular Comorbidity in Children with CKD (4 C) should help to delineate the evolution of disturbances in mineral metabolism and its adverse effects on growth, CKD progression and cardiovascular outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544696      PMCID: PMC4889119          DOI: 10.1007/s12098-012-0765-1

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  65 in total

1.  K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.

Authors: 
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

Review 2.  Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.

Authors:  D L Andress
Journal:  Kidney Int       Date:  2006-01       Impact factor: 10.612

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  A new mechanism for induced vitamin D deficiency in calcium deprivation.

Authors:  M R Clements; L Johnson; D R Fraser
Journal:  Nature       Date:  1987 Jan 1-7       Impact factor: 49.962

5.  Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

Authors:  Steven Fishbane; Harini Chittineni; Michal Packman; Paula Dutka; Nicole Ali; Nicole Durie
Journal:  Am J Kidney Dis       Date:  2009-07-12       Impact factor: 8.860

6.  25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity.

Authors:  C B Langman; A T Mazur; R Baron; M E Norman
Journal:  J Pediatr       Date:  1982-05       Impact factor: 4.406

7.  Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy.

Authors:  Xiaoyue Tan; Weichun He; Youhua Liu
Journal:  Kidney Int       Date:  2009-09-16       Impact factor: 10.612

8.  Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?

Authors:  Alex J Brown
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12-27       Impact factor: 4.292

9.  Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3.

Authors:  B P Halloran; P Schaefer; M Lifschitz; M Levens; R S Goldsmith
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

10.  Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D.

Authors:  Michael F Holick; Rachael M Biancuzzo; Tai C Chen; Ellen K Klein; Azzie Young; Douglass Bibuld; Richard Reitz; Wael Salameh; Allen Ameri; Andrew D Tannenbaum
Journal:  J Clin Endocrinol Metab       Date:  2007-12-18       Impact factor: 5.958

View more
  2 in total

Review 1.  Vitamin D and Temporomandibular Disorders: What Do We Know So Far?

Authors:  Andreea Kui; Smaranda Buduru; Anca Labunet; Silvia Balhuc; Marius Negucioiu
Journal:  Nutrients       Date:  2021-04-14       Impact factor: 5.717

2.  Vitamin D3 alleviates cigarette smoke extract-mediated epithelial-mesenchymal transition and fibrogenesis by upregulating CC16 expression in bronchial epithelial cells.

Authors:  Yajun Mao; Hong Feng
Journal:  Exp Ther Med       Date:  2022-03-29       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.